Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

NCT05778071 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

165

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hypoparathyroidism
Endocrine System Diseases
Parathyroid Diseases

Interventions

COMBINATION_PRODUCT: eneboparatide
COMBINATION_PRODUCT: Placebo

Sponsor

Alexion Pharmaceuticals, Inc.

Collaborators

[object Object]